IMR Press / EJGO / Volume 19 / Issue 5 / pii/1988215

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

p53 expression in ovarian carcinoma with regard to second-look findings

Show Less
1 Department of Pathology, Division of Gynecologic Oncology, Hacettepe University School of Medicine, Ankara, Turkey
2 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University School of Medicine, Ankara, Turkey
3 Department of Obstetrics and Gynecology, Departments of Obstetrics and Gynecology and Pathology, Division of Gynecologic Oncology, Hacettepe University School of Medicine, Ankara, Turkey
Eur. J. Gynaecol. Oncol. 1998, 19(5), 501–502;
Published: 10 October 1998
Abstract

Forty-eight (48) cases of ovarian carcinoma subjected to primary surgery and platinum based chemotherapy followed by second­look laparotomy (SLL) were analyzed with respect to p53 status. Overall aberrant p53 accumulation was observed in 20 (41.6%) out of 48 patients. While one out of 5 patients (20.0%) with stage 1-11 disease showed positive p53 staining, 19 out of 43 patients (44.1 %) with stage III disease were found to be positive for p53. According to the histologic types, 41.9% of serous (13/31), 33.3% of endometrioid (2/6), 50.0% of transitional (2/4), 40.0% of mixed (2/5) and 50,0% of mucinous types of tumors showed abnormal expression of p53. p53 positivity was found in 12 (54.5%) out of 22 SLL (+) patients while only 8 (30.7%) were p53 positive out of 26 with SLL (-) patients. Cases with abnormal p53 accumulation tended to be SLL positive, however, the difference was not significant.

Share
Back to top